drugset / Trial / NCT01587508

Study Comparing A New Drug Containing The Combination Meloxicam And Cyclobenzaprine In The Treatment Of Acute Lumbago

NCT01587508

Phase 3 Withdrawn Eurofarma Laboratorios S.A.
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to assess the efficacy end tolerability of a new drug containing the combination meloxicam and cyclobenzaprine (7,5/10mg) and the same components alone in the treatment of acute lumbago.

Timeline

Start
2013-05
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Meloxicam Small molecule 7.5 mg Oral
Comparator cyclobenzaprine Small molecule 10 mg Oral

Indications

No indication recorded.